Ignite Creation Date:
2024-05-05 @ 5:03 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00377065
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2016-04-22
First Post:
2006-09-14
Brief Title:
Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy 0518-023
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy OBT in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options
Status:
APPROVED_FOR_MARKETING
Status Verified Date:
2016-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a treatment use study to provide early access to MK0518 for the treatment of HIV-1 infection in patients who have limited or no treatment options due to virological failure resistance or intolerance to multiple antiretroviral regimens Enrollment in this study is patient driven Investigators are not proactively assigned There is no target sample size and duration of the study is indefinite For information on how to enroll in the study see link below
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MK0518-023 | None | None | None |
| 2006_031 | None | None | None |